NewLink Genetics has achieved a milestone under the license and collaboration agreement with Merck for the development of the rVSV-EBOV (Ebola) vaccine candidate. NewLink Genetics will receive a $20 million payment for the initiation of a key clinical trial for the vaccine.   The rVSV-EBOV vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC), and licensed by BioProtection Systems, Inc., a wholly-owned subsidiary of NewLink Genetics. PHAC will be entitled to a p...